Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 15, 23 | -0.67 Decreased by -48.89% | -0.60 Decreased by -19.44% |
Mar 29, 23 | -0.61 Decreased by -74.29% | -0.62 Increased by +2.60% |
Nov 14, 22 | -0.56 Decreased by -115.38% | -0.50 Decreased by -24.00% |
Aug 15, 22 | -0.49 Increased by +97.94% | -0.45 Decreased by -19.75% |
May 16, 22 | -0.45 | -0.28 Decreased by -216.84% |
Mar 30, 22 | -0.35 | -0.31 Decreased by -41.62% |
Nov 15, 21 | -0.26 | -0.26 |
Aug 16, 21 | -23.80 | -0.16 Decreased by -92.34 K% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Mar 31, 23 | 0.00 Decreased by N/A% | -15.40 M Decreased by -42.59% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0.00 Decreased by N/A% | -15.02 M Decreased by -72.73% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0.00 Decreased by N/A% | -13.02 M Decreased by -110.61% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0.00 Decreased by N/A% | -11.77 M Decreased by -103.76% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 0.00 Decreased by N/A% | -10.80 M Decreased by -288.39% | Decreased by N/A% Decreased by N/A% |
Dec 31, 21 | 0.00 Decreased by N/A% | -8.70 M Decreased by -137.23% | Decreased by N/A% Decreased by N/A% |
Sep 30, 21 | 0.00 Decreased by N/A% | -6.18 M Decreased by -168.05% | Decreased by N/A% Decreased by N/A% |
Jun 30, 21 | 0.00 Decreased by N/A% | -5.78 M Decreased by -162.26% | Decreased by N/A% Decreased by N/A% |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.